Patents Assigned to GlaxoSmithKline LLC
  • Thiazolopyrimidinone derivatives as PI3 kinase inhibitors
    Patent number: 8410095
    Abstract: This invention relates to novel compounds of formula (I): and derivatives thereof useful for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: April 2, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Hong Lin, Juan I. Luengo, Ralph A. Rivero, Mark James Schulz, Ren Xie, Jin Zeng
  • Methods for synthesis of encoded libraries
    Patent number: 8410028
    Abstract: The present invention provides a method of synthesizing libraries of molecules which include an encoding oligonucleotide tag.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: April 2, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Barry Morgan, Stephen Hale, Christopher C. Arico-Muendel, Matthew Clark, Richard Wagner, David I. Israel, Malcolm L. Gefter, Dennis Benjamin, Nils Jakob Vest Hansen, Malcolm J. Kavarana, Steffan Phillip Creaser, George J. Franklin, Paolo A. Centrella, Raksha A. Acharya
  • Quinoline derivatives as P13 kinase inhibitors
    Patent number: 8404837
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: March 26, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Nicholas D. Adams, Joelle Lorraine Burgess, Michael Gerard Darcy, Carla A. Donatelli, Steven David Knight, Kenneth Allen Newlander, Lance Ridgers, Martha A. Sarpong, Stanley J. Schmidt
  • PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20130072487
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Application
    Filed: November 2, 2012
    Publication date: March 21, 2013
    Applicant: GLAXOSMITHKLINE LLC
    Inventor: GLAXOSMITHKLINE LLC
  • Chemical Compounds
    Publication number: 20130072690
    Abstract: Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts.
    Type: Application
    Filed: November 15, 2012
    Publication date: March 21, 2013
    Applicant: GLAXOSMITHKLINE LLC
    Inventor: GLAXOSMITHKLINE LLC
  • Calcilytic compounds
    Patent number: 8399517
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: March 19, 2013
    Assignee: GlaxoSmithKline, LLC
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes
    Patent number: 8394808
    Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: March 12, 2013
    Assignee: Glaxosmithkline LLC
    Inventors: Ivan Leo Pinto, Shahzad Sharooq Rahman, Neville Hubert Nicholson
  • Deuterated benzene sulfonamide thiazole compounds
    Patent number: 8389723
    Abstract: Deuterated forms of N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and pharmaceutical compositions containing the same.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: March 5, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Jerry Leroy Adams, Dashyant Dhanak, Dirk A. Heerding, Calvin O. Manning
  • PYRROLO [3,2-D] PYRIMIDIN-3-YL DERIVATIVES USED AS ACTIVATORS OF AMPK
    Publication number: 20130053407
    Abstract: Pyrrolopyrimidones compounds of the formula (I), salts thereof, and pharmaceutical compositions containing them are disclosed herein, as well as methods for their use in medicine, for instance as activators of AMPK.
    Type: Application
    Filed: May 3, 2011
    Publication date: February 28, 2013
    Applicant: GlaxoSmithKline LLC
    Inventors: Olivier Mirguet, Anne Marie Jeanne Bouillot
  • Method for customized dispensing of variable dose drug combination products for individualizing of therapies
    Patent number: 8383579
    Abstract: Generally the method involves identifying the concentration of each of two or more active therapeutics tailored to treat a particular patient's unique metabolism and one or more diseases, communicating that information to a producer who has multiple fixed or variable concentrations of each active available, where the producer then combines the individual concentrations of each active into single units such as a tablets or pills, and distributes those indirectly or directly to the patient.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: February 26, 2013
    Assignee: Glaxosmithkline, LLC
    Inventors: Richard L. Kirsh, Steven D. Finkelmeier, Robert Glinecke, Luigi Martini
  • Chemical compounds
    Patent number: 8383635
    Abstract: The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, and R4 are defined below. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: February 26, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis Louis Atkinson, Jeffrey Michael Axten, Maria Cichy-Knight, Michael Lee Moore, Vipulkumar Kantibhai Patel, Xinrong Tian, Christopher Roland Wellaway, Allison K. Dunn
  • Indole carboxamides as IKK2 inhibitors
    Patent number: 8372875
    Abstract: The invention is directed to novel indole carboxamide compounds. Specifically, the invention is directed to compounds according to formula (I): wherein R1, R2, R3, R4, and m are as defined herein. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: February 12, 2013
    Assignee: GlaxoSmithKline, LLC
    Inventor: Jeffrey K. Kerns
  • PROCESS FOR PREPARING BENZOXABOROLES
    Publication number: 20130035501
    Abstract: The present invention is a process comprising contacting a compound of formula 6: or a pharmaceutically acceptable salt thereof; with a deprotecting reagent to form a compound of formula A: or a pharmaceutically acceptable salt thereof; where R is H or OR1; R1 and each R1? are protecting groups; R1? is H or OH, and n is 0, 1, 2, 3, 4, or 5.
    Type: Application
    Filed: April 6, 2011
    Publication date: February 7, 2013
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Jose J. Conde, John Anthony Kowalski, Matthew Allen Zajac
  • Chemical Compounds
    Publication number: 20130029938
    Abstract: Compounds of Formula I and methods for treating metabolic disorders are disclosed.
    Type: Application
    Filed: April 27, 2011
    Publication date: January 31, 2013
    Applicant: GlaxoSmithKline LLC
    Inventors: Christopher Joseph Aquino, Jon Loren Collins, David John Cowan, Yulin Wu
  • Azaindole Compounds and Methods for Treating HIV
    Publication number: 20130018049
    Abstract: Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV).
    Type: Application
    Filed: July 12, 2012
    Publication date: January 17, 2013
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Martha Alicia De La Rosa, Brian Alvin Johns, Emile Johann Velthuisen, Jason Weatherhead, Vicente Samano
  • Chemical compounds
    Patent number: 8354406
    Abstract: The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: January 15, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Jianghe Deng, Jeffrey K. Kerns, Qi Jin, Guoliang Lin, Xichen Lin, Michael Lindenmuth, Christopher Neipp, Hong Nie, Sonia M Thomas, Katherine L. Widdowson
  • TRPV4 ANTAGONISTS
    Publication number: 20130012499
    Abstract: The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: March 23, 2011
    Publication date: January 10, 2013
    Applicant: GlaxoSmithKline LLC
    Inventors: Carl A. Brooks, Mui Cheung, S. Eidam Hilary, Ryan M. Fox, Mark A. Hilfiker, Eric S. Manas
  • Inhibitors of Akt activity
    Patent number: 8338434
    Abstract: Invented are novel pyrazole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: December 25, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark Andrew Seefeld, Meagan B. Rouse
  • Methods for administering long-lasting hypoglycemic agents
    Patent number: 8338369
    Abstract: The present invention relates to methods and pharmaceutical compositions relating to administering hypoglycemic agents and/or GLP-1 agonists wherein the mean maximum plasma concentration (Cmax) and/or Area Under the Curve (AUC) values of the hypoglycemic agent are increased and/or sustained.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: December 25, 2012
    Assignee: Glaxosmithkline LLC
    Inventors: Mark A. Bush, Jessica E. Matthews, Susan E. Walker
  • Nasal dilator
    Patent number: D673270
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: December 25, 2012
    Assignee: GlaxoSmithKline, LLC
    Inventors: Jeffrey S. Brunner, Gustav R Fenton, Snigdha Mishra